000100713 001__ 100713
000100713 005__ 20230519145409.0
000100713 0247_ $$2doi$$a10.3390/jcm10030489
000100713 0248_ $$2sideral$$a123333
000100713 037__ $$aART-2021-123333
000100713 041__ $$aeng
000100713 100__ $$aMarin-Oto, M.
000100713 245__ $$aNocturnal Hypoxemia and CT Determined Pulmonary Artery Enlargement in Smokers
000100713 260__ $$c2021
000100713 5060_ $$aAccess copy available to the general public$$fUnrestricted
000100713 5203_ $$aBackground: Pulmonary artery enlargement (PAE) detected using chest computed tomography (CT) is associated with poor outcomes in chronic obstructive pulmonary disease (COPD). It is unknown whether nocturnal hypoxemia occurring in smokers, with or without COPD, obstructive sleep apnoea (OSA) or their overlap, may be associated with PAE assessed by chest CT.
Methods: We analysed data from two prospective cohort studies that enrolled 284 smokers in lung cancer screening programs and completing baseline home sleep studies and chest CT scans. Main pulmonary artery diameter (PAD) and the ratio of the PAD to that of the aorta (PA:Ao ratio) were measured. PAE was defined as a PAD >= 29 mm in men and >= 27 mm in women or as a PA:Ao ratio > 0.9. We evaluated the association of PAE with baseline characteristics using multivariate logistic models.
Results: PAE prevalence was 27% as defined by PAD measurements and 11.6% by the PA:Ao ratio. A body mass index >= 30 kg/m(2) (OR 2.01; 95%CI 1.06-3.78), lower % predicted of forced expiratory volume in one second (FEV1) (OR 1.03; 95%CI 1.02-1.05) and higher % of sleep time with O-2 saturation < 90% (T90) (OR 1.02; 95%CI 1.00-1.03), were associated with PAE as determined by PAD. However, only T90 remained significantly associated with PAE as defined by the PA:Ao ratio (OR 1.02; 95%CI 1.01-1.03). In the subset group without OSA, only T90 remains associated with PAE, whether defined by PAD measurement (OR 1.02; 95%CI 1.01-1.03) or PA:Ao ratio (OR 1.04; 95%CI 1.01-1.07).
Conclusions: In smokers with or without COPD, nocturnal hypoxemia was associated with PAE independently of OSA coexistence.
000100713 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000100713 590__ $$a4.964$$b2021
000100713 592__ $$a1.04$$b2021
000100713 594__ $$a4.4$$b2021
000100713 591__ $$aMEDICINE, GENERAL & INTERNAL$$b55 / 172 = 0.32$$c2021$$dQ2$$eT1
000100713 593__ $$aMedicine (miscellaneous)$$c2021$$dQ1
000100713 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000100713 700__ $$aSeijo, L.M.
000100713 700__ $$aDivo, M.
000100713 700__ $$aBastarrika, G.
000100713 700__ $$aEzponda, A.
000100713 700__ $$aCalvo, M.
000100713 700__ $$aZulueta, J.J.
000100713 700__ $$aGallardo, G.
000100713 700__ $$aCabezas, E.
000100713 700__ $$aPeces-Barba, G.
000100713 700__ $$aPerez-Warnisher, M.T.
000100713 700__ $$0(orcid)0000-0001-9096-2294$$aMarin, J.M.$$uUniversidad de Zaragoza
000100713 700__ $$aCelli, B.R.
000100713 700__ $$aCasanova, C.
000100713 700__ $$aDe-Torres, J.P.
000100713 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000100713 773__ $$g10, 3 (2021), 489 [12 pp]$$pJ. clin.med.$$tJournal of Clinical Medicine$$x2077-0383
000100713 8564_ $$s462346$$uhttps://zaguan.unizar.es/record/100713/files/texto_completo.pdf$$yVersión publicada
000100713 8564_ $$s2724579$$uhttps://zaguan.unizar.es/record/100713/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000100713 909CO $$ooai:zaguan.unizar.es:100713$$particulos$$pdriver
000100713 951__ $$a2023-05-18-13:53:26
000100713 980__ $$aARTICLE